Last updated: October 4, 2022
Sponsor: Peking Union Medical College Hospital
Overall Status: Active - Recruiting
Phase
1/2
Condition
Brain Tumor
Cancer/tumors
Neurofibromatosis
Treatment
N/AClinical Study ID
NCT05569434
PekingUMCH-GBM093
Ages 18-80 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- glioma patients highly suggested by MRI or histologically confirmed;
- 68Ga-P16-093 PET/CT and MRI within two weeks;
- signed written consent.
Exclusion
Exclusion Criteria:
- known allergy against PSMA;
- any medical condition that in the opinion of the investigator may significantlyinterfere with study compliance.
Study Design
Total Participants: 50
Study Start date:
November 28, 2021
Estimated Completion Date:
December 31, 2024
Study Description
Connect with a study center
Peking Union Medical College Hospital
Beijing, Beijing 100730
ChinaActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.